Table 1.
Year | Country | No. | PCV Use in National Immunity Program | Prevalent Serotypes Pre-PCV | Prevalent Serotypes Post-PCV | PCV Coverage |
References |
---|---|---|---|---|---|---|---|
1997–2006 | Utah | 33 | PCV-7: 2001, 2 + 1 | Pre-PCV7: 6B (40.0%), 19F (20.0%), 1 (20.0%) and 6A (20.0%) | Post-PCV7: 4 (3.6%), 1 (7.1%), 3 (39.3%), 7 (3.6%), 8 (3.6%), 17 (3.6%), 19 (14.3%) and 19A (14.3%) | PCV-7: 80% | [20] |
2005–2019 | Italy | 43 | PCV-13: 2010, 2 + 1 | Pre-PCV13: 1 (18.2%), 3 (27.3%), 5 (9.1%), 7F (9.1%) and 19A (9.1%) | Early post-PCV13: 1 (25.0%), 5 (12.5%) and 7F (12.5%) Late post-PCV13: 3 (80.0%) and 12 (20.0%) |
PCV-7: 62.8% PCV-13: 23.3% |
[23] |
2012–2016 | Catalonia, Spain | 35 | PCV-13: 2016, 2 + 1 | Not mentioned | Post-PCV13: 1 (14.3%), 3 (48.6%), 6B (2.9%), 7F (2.9%), 14 (5.7%), 19A (8.6%), 7A (5.7%), 6A/C (2.9%) and 12F/A/44/46 (2.9%) | PCV-13: 14.3% | [24] |